KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Gains from Investment Securities (2016 - 2025)

BeOne Medicines (ONC) has disclosed Gains from Investment Securities for 11 consecutive years, with -$17.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 65.54% to -$17.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 56.78% decrease, with the full-year FY2025 number at $1.2 million, down 56.78% from a year prior.
  • Gains from Investment Securities was -$17.9 million for Q4 2025 at BeOne Medicines, up from -$57.9 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $183.6 million in Q4 2021 to a low of -$57.9 million in Q3 2025.
  • A 5-year average of $11.0 million and a median of $4.8 million in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 3073.33% in 2023, then soared 528.88% in 2025.
  • BeOne Medicines' Gains from Investment Securities stood at $183.6 million in 2021, then tumbled by 112.81% to -$23.5 million in 2022, then skyrocketed by 42.58% to -$13.5 million in 2023, then tumbled by 284.39% to -$51.9 million in 2024, then skyrocketed by 65.54% to -$17.9 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Gains from Investment Securities are -$17.9 million (Q4 2025), -$57.9 million (Q3 2025), and $61.4 million (Q2 2025).